The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

  • End date
    May 21, 2023
  • participants needed
  • sponsor
    Beijing Cancer Hospital
Updated on 24 May 2022


This ia a single-arm, not-randomized, open-label phase II study. The purpose of this study is to evaluate the safety and efficacy of KN046 (PD-L1 /CTLA-4 Bispecific antibody) combined with Lenvatinib(TKI) for the treatment of advanced hepatocellular carcinoma.

Condition HCC
Treatment Lenvatinib, KN046
Clinical Study IdentifierNCT04542837
SponsorBeijing Cancer Hospital
Last Modified on24 May 2022


Yes No Not Sure

Inclusion Criteria

Has a diagnosis of hepatocellular carcinoma confirmed by histology or cytology;
Barcelona Clinic Liver Cancer (BCLC) Stage B or C;
Age ≥18 years or ≤75 years for both genders;
ECOG performance status: 0-1;
Child Pugh score≤7;
LVEF≥50% or above LLN of the research institution;
Enough organ function;
Has at least one measurable lesion based on RECIST 1.1;
Life expectancy ≥3 months;
Patients must be able to understand and willing to sign a written informed consent document;

Exclusion Criteria

Fibrous lamina hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma etc
Tumor thrombus invasion at the main portal vein (Vp4), inferior vena cava or heart involvement
Subjects who have previously received immune checkpoint inhibitors (such as anti-PD-1/L1, CTLA-4, etc.)
Subjects who have received liver local treatment (transcatheter chemoembolization, transcatheter embolization, hepatic artery perfusion, radiotherapy, radioembolization or ablation) within 4 weeks before administration
Subjects who need corticosteroids or immunosuppressive agents for systemic therapy
Any previous or current active autoimmune disease or history of autoimmune disease
History of hepatic encephalopathy or liver transplantation
History of interstitial lung disease or non-infectious pneumonia
History of allergic reactions to related drugs
Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients undergoing total gastrectomy
With serious systemic diseases such as heart disease and cerebrovascular disease, and the condition is unstable or uncontrollable
Subjects with clinically significant gastrointestinal bleeding or thrombosis or embolic events within 6 months
Untreated hepatitis infection: HBV DNA>2000IU/ml or10000 copies/ml, HCV RNA> 1000copy/ml, both HbsAg and anti-HCV body are positive
Evidence of active pulmonary tuberculosis (TB)
Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
Pleural effusion, ascites and pericardial effusion with clinical symptoms or needing drainage
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note